EMA advisory committee recommends approval of Eli Lilly's oral obesity drug Foundayo
LLY Lilly(Eli) & Co
$1257.03 +0.43%
View chart & analysis → - 1The European Medicines Agency (EMA) advisory committee has recommended approval for Eli Lilly's (LLY) once-daily oral obesity drug Foundayo
- 2The target audience includes adults with obesity, overweight adults with related conditions, and adults with type 2 diabetes, while LLY shares rose approximately 7.8% this week, marking their largest weekly gain in four months
- 3Final approval from the European Commission remains pending, with decisions typically made within 67 days of recommendation, though Lilly has not disclosed the expected launch date
So what's the key point?
Advisory committee members from the European drug regulatory body recommended the approval of Lilly's oral obesity medication. Although final approval is still pending, Lilly's stock price rose approximately 7.8% this week.
Source Stocktwits +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.